Alnylam clears phase 2 test for Regeneron-partnered nephropathy med, as it looks to play catch-up against Calliditas

After achieving its main phase 2 trial goal, Alnylam’s immunoglobulin A nephropathy (IgAN) treatment has now hit several secondary endpoints, demonstrating further potential for the Regeneron-partnered therapeutic as the companies aim to catch up to Calliditas Therapeutics' approved med Tarpeyo.